title: Comparison of benefits on myocardial performance of cellular cardiomyoplasty with skeletal myoblasts and fibroblasts.
abstract: Cellular cardiomyoplasty (CCM), or introduction of immature cells into terminally injured heart, can mediate repair of chronically injured myocardium. Several different cell types, ranging from embryonic stem cells to autologous skeletal myoblasts, have been successfully propagated within damaged heart and shown to improve myocardial performance. However, it is unclear if the functional advantages associated with CCM depend upon the use of myogenic cells or if similar results can be seen with other cell types. Thus, we compared indices of regional contractile (systolic) and diastolic myocardial performance following transplantation of either autologous skeletal myoblasts (Mb) or dermal fibroblasts (Fb) into chronically injured rabbit heart. In vivo left ventricular (LV) pressure (P) and regional segment length (SL) were determined in 15 rabbits by micromanometry and sonomicrometry 1 week following LV cryoinjury (CRYO) and again 3 weeks after autologous skeletal Mb or dermal Fb transplantation. Quantification of systolic performance was based on the linear regression of regional stroke work and end-diastolic (ED) SL. Regional diastolic properties were assessed using the curvilinear relationships between LVEDP and strain (epsilon) as well as LVEDP and EDSL. At study termination, cellular engraftment was characterized histologically in a blinded fashion. Indices of diastolic performance were improved following CCM with either Mb or Fb. However, only Mb transplantation improved systolic performance; Fb transfer actually resulted in a significant decline in systolic performance. These data suggest that both contractile and noncontractile cells can improve regional material properties or structural integrity of terminally injured heart, as reflected by improvements in diastolic performance. However, only Mb improved systolic performance in the damaged region, supporting the role of myogenic cells in augmenting contraction. Further studies are needed to define the mechanism by which these effects occur and to evaluate the long-term safety and efficacy of CCM with any cell type.
authors.affiliation: Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: K A
authors.initials: KA
authors.lastname: Hutcheson
authors.forename: B Z
authors.initials: BZ
authors.lastname: Atkins
authors.forename: M T
authors.initials: MT
authors.lastname: Hueman
authors.forename: M B
authors.initials: MB
authors.lastname: Hopkins
authors.forename: D D
authors.initials: DD
authors.lastname: Glower
authors.forename: D A
authors.initials: DA
authors.lastname: Taylor
mesh_terms: D000818:Animals; D009202:Cardiomyopathies / Q000473:pathology / Q000601:surgery; D018421:Cardiomyoplasty / Q000379:methods*; D017690:Cell Transplantation; D003971:Diastole; D005347:Fibroblasts / Q000637:transplantation*; D006321:Heart / Q000033:anatomy & histology / Q000502:physiology*; D006801:Humans; D008856:Microscopy, Fluorescence; D018482:Muscle, Skeletal / Q000166:cytology* / Q000637:transplantation; D009206:Myocardium / Q000166:cytology / Q000473:pathology; D011817:Rabbits; D012867:Skin / Q000166:cytology; D013599:Systole; D014182:Transplantation, Autologous